WCLC2020: Combining ipilimumab plus pembrolizumab did not add clinical benefit for patients NSCLC

Professor Michael Boyer, The University of Sydney presents in this MEDtalk the results of Keynote-598, showing that addition of ipilimumab to pembrolizumab did not add clinical benefit but did add toxicity. The combination did not demonstrate incremental benefit compared with pembrolizumab monotherapy in terms of either overall survival or progression-free survival. Instead the combination demonstrated a higher incidence of grade 3-5 adverse events , serious AEs, and AEs leading to either treatment discontinuation or death compared with the single agent.